FMP
NASDAQ
2.12 USD
0.06 (2.83%)
Dr. Jonathan E. Lim M.D.
Healthcare
Biotechnology
https://www.erasca.com
NASDAQ
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
0001761918
US29479A1088
29479A108
10835 Road to the Cure
858 465 6511
US
129
Jul 16, 2021
0001761918
NASDAQ
Biotechnology
Healthcare
29479A108
US29479A1088
US
2.12
1.14
778.69k
320.3M
-
1.51-3.375
1.88
-
-
-
-
-2.55
-
https://www.erasca.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.